What Is Substance P? Benefits, Research & Safety
A key neuropeptide involved in pain transmission, inflammation, and mood regulation, and the target of the first neuropeptide receptor antagonist drug.
UK summary: Endogenous neuropeptide involved in pain and neurogenic inflammation. Not a medicine; NK1-receptor antagonists (e.g. aprepitant) are licensed UK antiemetics that work against Substance P signalling.
Quick Facts
Overview
Substance P — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous neuropeptide involved in pain and neurogenic inflammation. Not a medicine; NK1-receptor antagonists (e.g. aprepitant) are licensed UK antiemetics that work against Substance P signalling.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
- EU: Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
- Notes: Substance P itself is not a therapeutic but is crucial for understanding pain and inflammation. NK1R antagonists represent an important therapeutic class. Research continues into broader applications of NK1R blockade.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Substance P supplements treat chronic pain.
- Oral 'pain peptide' lifts pain naturally.
07Common internet claims
- Marketed as a wellness supplement on the 'nature's pain pathway' story.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Substance P supplements affect pain perception” | E | No | High | Substance P cannot be taken orally; pain treatment requires licensed medicines and clinical assessment. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Oral peptide is degraded and biologically inert.
- Injectable use is research-stage and not safety-tested.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
14EU legal position
Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
15What this page cannot tell you
- What 'Substance P supplements' actually contain.
- Whether they produce any measurable physiological effect.
16Last reviewed
17Citation quality score
18Research gaps
- NK1-receptor antagonist drug development is the practical Substance P pathway pharmacology; not a supplement route.
19Safer alternatives / established care pathways
- NHS pain-clinic referral for chronic pain.
- Licensed analgesics per NICE NG193 / cause-specific guidelines.
- CBT for chronic-pain coping via NHS Talking Therapies.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What evidence-based pain management options are appropriate for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Understanding pain transmission mechanisms
- 2NK1R antagonists approved as anti-emetics (aprepitant/Emend)
- 3Potential target for chronic pain therapeutics
- 4Research into antidepressant effects of NK1R blockade
- 5Biomarker for neuroinflammatory conditions
- 6Role in wound healing and tissue repair
- 7Understanding neurogenic inflammation
Claim vs Evidence
How popular claims about Substance P stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Substance P supplements affect pain perception” | E | No | High | Substance P cannot be taken orally; pain treatment requires licensed medicines and clinical assessment. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Substance P itself is not administered therapeutically |
| Frequency | N/A |
| Duration | N/A |
| Notes | Substance P is an endogenous neuropeptide. Clinical interest focuses on NK1R antagonists that block Substance P's effects. Aprepitant (Emend) is the primary approved NK1R antagonist, used for prevention of chemotherapy-induced nausea. |
Administration Routes
Routes studied in research settings (educational only):
- Not administered therapeutically (endogenous neuropeptide)
- Used in research for pain/inflammation studies
| Half-Life | Stability |
|---|---|
| Very short (minutes) due to rapid enzymatic degradation by neutral endopeptidase | Rapidly degraded in vivo; research preparations require protease inhibitors |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Not administered therapeutically
Rare Risks & Concerns
- Elevated Substance P levels associated with chronic pain and inflammation
- Excessive neurogenic inflammation
- Contribution to inflammatory disease pathology
Contraindications
- Not a therapeutic agent
UK & EU Regulatory Context
🇬🇧 United Kingdom
Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
🇪🇺 European Union
Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
Clinical Studies Summary
Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis.
The application of dry needling can induce significant changes in pain-related biomarker levels in animal and human studies, providing insights into its underlying mechanisms of action and potential clinical effects.
Inflammatory Biomarkers in Irreversible Pulpitis and Pulp Necrosis: A Systematic Review and Meta-Analysis.
Both SIP and AIP exhibit pro-inflammatory profiles, with TNF-α elevated regardless of symptoms. Molecular biomarkers may better reflect pulp status than clinical signs.
Effects of Auricular Stimulation on Inflammatory Parameters: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
The influence of inflammatory cytokines seems to be mediated by AS. More research is needed to investigate the effects of AS on the immunologic system in addition to its clinical significance in high-quality RCT.
Neurochemical Alterations in Aggression: A Meta-Analysis.
The findings for the other neurochemicals all did not reach statistical significance. These findings suggest that reduced prefrontal NAA levels may serve as a neurobiological correlate of aggressive behaviours, with implications for developing assessment tools and targeted interventions.
Association between brain-gut peptides and depression: A systematic review and meta-analysis.
The findings suggest that increased serum concentrations of SP, CCK, and ghrelin are associated with depressive disorders, highlighting their potential as important biomarkers for the detection of depression. In contrast, the role of LEP in depression remains inconclusive and warrants further investigation.
Systemic neurokinin-1 receptor antagonists mitigate chronic pruritus: A systematic review and meta-analysis.
Our study suggests that systemic NK1R antagonists, particularly serlopitant and aprepitant, hold modest therapeutic effect for treating chronic pruritus, particularly in patients with nonmalignant dermatological conditions. Thus, clinicians can consider NK1R antagonists to effectively interrupt itch signaling in patients with chronic pruritus.
Registered Trials & Regulatory Status
10 of 15 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Postoperative Pain and Substance P Levels After Bioceramic vs Calcium Hydroxide Intracanal Medicaments in Symptomatic Apical Periodontitis
Status: Not Yet Recruiting · 28 participants · Future University in Egypt
Conditions: Symptomatic Apical Periodontitis
Substance P-Induced Migraine Attacks Without Aura
Status: Recruiting · 21 participants · Danish Headache Center
Conditions: Migraine
Effects of Substance P on Headache Induction in Healthy Individuals
Status: Not Yet Recruiting · 21 participants · Danish Headache Center
Conditions: Healthy Volunteers Only
EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION
Status: Recruiting · 24 participants · University Hospital, Rouen
Conditions: Apnea, Obstructive
Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P
Status: Recruiting · 51 participants · Melike Cengiz
Conditions: Meningitis, Diagnosis, Prognosis
The Effect of Different Intraradicular Cryotherapy on Post-operative Pain and the Level of Substance P
Status: Completed · 135 participants · Ain Shams University
Conditions: Post Operative Pain, Inflammation
Substance P Challenge in Healthy Participants
Status: Completed · 32 participants · GlaxoSmithKline
Conditions: Skin Diseases
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
Status: Terminated · 4 participants · Vanderbilt University Medical Center
Conditions: Hypertension
Substance P as a Biomarker to Evaluate the Reduction of Multiple Immunization Pain
Status: Completed · 132 participants · Jordan University of Science and Technology
Conditions: Immunisation Anxiety Related Reaction, Pain, Acute
The Effect of Beta-blockers in Substance P Levels and the Swallowing Function
Status: Unknown · 60 participants · Hospital de Mataró
Conditions: Beta Blockers, Swallowing Disorder, Substance P
Regional Anaesthesia and Substance P in Head and Neck Cancer
Status: Suspended · 40 participants · Charite University, Berlin, Germany
Conditions: Head and Neck Cancer
Neuropeptide Therapy of Recent Onset Type 1 Diabetes
Status: Unknown · 12 participants · Vanilloid Genetics Inc.
Conditions: Diabetes Mellitus, Type 1
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Substance P?
Source research-grade Substance P from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Substance P
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What evidence-based pain management options are appropriate for my situation?
Related Peptides
DSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreVasopressin
A hormone essential for water balance and blood pressure regulation, also involved in social behavior and stress responses.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn moreBeta-Endorphin
The body's natural opioid peptide involved in pain modulation, stress response, and reward, mediating the 'runner's high' and other euphoric states.
Learn more